In this editorial, Dr Rupert Payne, Consultant Editor on Prescriber, discusses the best ways of solving the problem of overprescribing in the
Articles: 30.01 January 2019
Chlamydia is a common sexually-transmitted infection caused by Chlamydia trachomatis bacteria. This article discusses its diagnosis and treatment, and considers the GP’s role in management.
NICE published a new guideline in September 2018 on the diagnosis and management of chronic heart failure in adults (NG106). This article provides a summary of the guideline and how it differs from previous NICE guidance and the 2016 SIGN guidance
Overactive bladder (OAB) is a symptom complex characterised by urinary urgency, with or without urgency incontinence, usually associated with increased daytime frequency and nocturia. This article discusses our current understanding of OAB and its recommended management
NICE recently recommended the janus kinase (JAK) inhibitor tofacitinib (Xeljanz) for second-line treatment of moderately to severely active ulcerative colitis. This article summarises the efficacy for tofacitinib in inflammatory bowel disease (ulcerative colitis and Crohn’s disease), and discusses a new JAK inhibitor, filgotinib, that has shown promise in Crohn’s disease
Awareness of the risks of medicines-related harm in the elderly can enhance medicines safety in vulnerable patients. This article examines the risk factors for medicines-related harm and the recommended strategies to reduce these risks
Peramivir (Alpivab) is an intravenous antiviral medicine licensed for the treatment of uncomplicated influenza in adults and children from the age of two years. This article examines its efficacy and adverse effects